Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9442187 | 0.87 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL11141100 | 0.87 | MEN1 (0.70) | KMT2AMEN1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL21972738 | 0.85 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1KDM4ENPC1 | |
| SCHEMBL9311985 | 0.81 | KMT2A (0.75) | KMT2AMEN1ALDH1A1KDM4ENPC1 | |
| SCHEMBL11551559 | 0.81 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5481312 | 0.81 | ALDH1A1 (0.60) | KMT2AMEN1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8626970 | 0.80 | HPGD (0.56) | KMT2AMEN1ALDH1A1KDM4ENPC1 | |
| SCHEMBL11143547 | 0.80 | POLB (0.70) | KMT2AMEN1ALDH1A1GAACYP1A2 | |
| SCHEMBL11031904 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4EHSD17B10NPC1RAB9A | |
| SCHEMBL11196307 | 0.79 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260187-A | Pyridone compounds and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-2102211-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-5716446-A | PRINTING INK; TONERS; POWDER COATING | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-10 | — | — | US | disclosed |
| US-5698705-A | BASED ON AMINOBENZIMIDAZOLONES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-16 | — | — | US | disclosed |
| US-5124331-A | Anticancer agents | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1992-06-23 | — | — | US | disclosed |
| EP-0364598-A1 | 3,4-dihydrothieno ¬2,3-d pyrimidine compounds and pharmaceutical application thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-04-25 | — | — | EP | disclosed |
| US-4623384-A | POSTEMERGENCE | STAUFFER CHEMICAL CO. (US) | 1986-11-18 | — | — | US | disclosed |
| US-4565570-A | PHENYLAMINO, NITRILE SUBSTITUTED | STAUFFER CHEMICAL COMPANY (US) | 1986-01-21 | — | — | US | disclosed |
| US-4474952-A | ORGANIC PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1984-10-02 | — | — | US | disclosed |
| US-4393217-A | ANXIOLYTICS, ANTIDEPRESSANTS | AMERICAN CYANAMID COMPANY (US) | 1983-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | KMT2A 3625/4885MEN1 1123/4885ALDH1A1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.